Opexa Therapeutics Inc (NASDAQ:OPXA)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular disease.


Player Avatar pugnaciously (30.11) Submitted: 11/14/2011 12:07:33 PM : Outperform Start Price: $5.44 OPXA Score: -148.89

Fast Track status just announced by the FDA for its multiple sclerosis drug, Tovaxin. It is currently in Stage IIb of clinical trials, thus far showing effectiveness where other drugs have failed. Namely treating SPMS - Secondary Progressive Multiple Sclerosis. It also is thus far effective in treating Relapsing Remitting MS. Thus, it's a potential double winner in combating the early and secondary form of the disease. “The TERMS trial was a landmark study in that it was the first time that a personalized immunotherapy of this nature was used to treat MS patients,” commented Edward Fox, MD, PhD, director of the MS Clinical of Central Texas, and a principal investigator in the TERMS study. “The results were encouraging in that they supported the continued development of Tovaxin in both relapsing remitting and secondary progressive MS.”

Report this Post 2 Replies
Member Avatar blessedbyhim (35.14) Submitted: 11/16/2011 12:34:07 AM
Recs: 0

I defer to my CAPS compadre Hans. He states that fast track status doesn't really help a stock as purported my numerous studies. I defer to him on this and suggest we put this misnomer to bed then.

Member Avatar pugnaciously (30.11) Submitted: 11/23/2011 7:27:14 PM
Recs: 0

I have commented on a couple of my own posts. I did not know this was such a CAPS faux paux. In fact, here I have said my original post here is just plain flat wrong with my other account- thus Hans knows more than I do and references the studies that show Fast Track status actually doesn't actually help the overall trajecture upward in the longer-term, of a biopharm stock. In fact, I attempted to put this misnomer to bed, directly hammering my own original thesis. To be able to admit that one is wrong is a good thing within investing. I will attempt to make sure I make no future recommends within my accounts upon statements made by the other account, hence no pumping my own ideas. I really did not intend this, and in fact just responded to Han's critique on the account I happened to be on atm, which was the other one. Additionally, I just responded to with the account I was currently on, not with the attempt to pump myself. Again, sorry folks, it won't happen in the future.

Featured Broker Partners